Navigation Links
Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results

SUNNYVALE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its first fiscal quarter ended September 30, 2008. The net loss for the first quarter of fiscal 2009, was $6.5 million, or $0.25 per share, compared to a net loss of $6.8 million, or $0.26 per share, in the first quarter of fiscal 2008.

Total operating expenses were $6.6 million in the first quarter of fiscal 2009, including $1.4 million of severance related share-based compensation expense and $0.5 million of severance expense. Excluding the $1.9 million of severance related share-based compensation and severance expenses, total expenses were $4.7 million in the first quarter of fiscal 2009 compared to $7.3 million for the first quarter of fiscal 2008, a decrease of $2.6 million. Excluding $1.4 million in severance related share-based compensation expense, share-based compensation expense was $0.4 million in the first quarter of fiscal 2009 compared to $0.7 million in the first quarter of fiscal 2008. The decrease of $2.6 million in total operating expenses, after excluding the severance related expenses, in the first quarter of fiscal 2009 was primarily due to reduced personnel expenses due to lower headcount and reduced manufacturing costs and outside preclinical expenses associated with the company's HDAC, Btk and Factor VIIa inhibitor programs.

As of September 30, 2008, the company's cash, cash equivalents and marketable securities totaled $12.5 million compared to $16.8 million at June 30, 2008.

Robert W. Duggan stated, "Entering my second month as Chairman and Interim CEO, there are a few observations I wish to share with my fellow stakeholders. Pharmacyclics is a company consisting of high quality people. Most of them are deeply experienced with our lead molecule motexafin gadolinium. In acquiring three promising compounds from Celera, we were very fortunate to inherit a group of experienced scientists that have been closely associated with each of these products from their onset. Our scientists are making great strides in forwarding a product pipeline that is novel, differentiated and full of potential. Without question, these are challenging times and historically those that rise up to face the challenges before them and put solutions into action gain strength in the process and become a good deal more viable than ever before. This is our intention. At Pharmacyclics we are dedicated to advancing our small molecule cancer drug candidates through clinical trials and establishing ourselves as a viable pharmaceutical company bringing real solutions to unmet or underserved patients' needs.

"Our executive team looks forward to providing shareholders, current and prospective, with a full update concerning our progress and plans for the future at our annual meeting scheduled for December 12, 2008."

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and immune diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at Pharmacyclics(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about future plans and timelines for our preclinical studies and clinical trials, progress of and reports of results from preclinical studies and clinical trials, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with our ability to obtain future financing and fund the product development of our pipeline; our ability to estimate accurately the amount of cash to be used to fund operations over the next 12 months; unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2008 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


Pharmacyclics, Inc.

(a development stage enterprise)

Condensed Statements of Operations

(unaudited) (in thousands, except per share data)

Three Months Ended


2008 2007

Operating expenses:

Research and development $3,203 $5,240

General and administrative 3,439 2,067

Total operating expenses 6,642 7,307

Loss from operations (6,642) (7,307)

Interest and other, net 100 477

Net loss $(6,542) $(6,830)

Basic and diluted net loss per share $(0.25) $(0.26)

Shares used to compute basic and

diluted net loss per share 26,015 25,958

Condensed Balance Sheets

(unaudited, in thousands)

September 30, June 30,

2008 2008


Cash, cash equivalents and

marketable securities* $12,467 $16,755

Other current assets 560 401

Total current assets 13,027 17,156

Property and equipment, net 615 688

Other noncurrent assets 290 523

$13,932 $18,367

Liabilities and stockholders' equity

Current liabilities $2,160 $1,851

Long-term obligations 70 71

Stockholder's equity 11,702 16,445

$13,932 $18,367

* Marketable securities $5,679 $4,495

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
2. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
3. Pharmacyclics Announces It Received Nasdaq Notification
4. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. United Therapeutics Reports Third Quarter 2008 Financial Results
8. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
9. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
Post Your Comments:
(Date:11/30/2015)... , November 30, 2015 TapImmune, ... the development of innovative peptide and gene-based immunotherapeutics and ... today announced it will be presenting at the 8 ... 1, 2015 at 2.30 PM PT. Dr. John ... Advisor will be giving the presentation and will join ...
(Date:11/30/2015)... and MAGDEBURG, Germany , November 30, 2015 ... in Vienna, Austria to be ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") ... its Internet-delivered NovaVision Therapy Suite at the 3rd European ...
(Date:11/28/2015)... ... November 28, 2015 , ... • Jeon Jin Bio Corp, a ... rodent control solutions , Bird Free, an ... across all sensory modalities including visual, smell, taste and touch, enabling safe, effective avian ...
(Date:11/26/2015)... 26, 2015 ... Accutest Research Laboratories, a leading independent ... (CRO), has formed a strategic partnership ... Temple Health for joint work on ... ) , --> ...
Breaking Biology Technology:
(Date:11/17/2015)... Calif. , Nov. 17, 2015  Vigilant Solutions ... has joined its Board of Directors. ... Board after recently retiring from the partnership at TPG ... 107 companies with over $140 Billion in revenue.  He ... improvement across all the TPG companies, from 1997 to ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
(Date:11/9/2015)... JOSE, Calif. , Nov. 9, 2015  Synaptics ... human interface solutions, today announced broader entry into the ... vehicle-specific solutions that match the pace of consumer electronics ... and biometric sensors are ideal for the automotive industry ... vehicle. Europe , ...
Breaking Biology News(10 mins):